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1. Introduction 
Respiratory allergy (allergic rhino conjunctivitis and allergic asthma), is community 
encountered medical condition that cause substantial morbidity and mortality worldwide 
[1]. Asthma is still remains a concerning and coasty epidemic that is largely unexplained [2]. 
In Iraq, both allergic rhinitis and asthma cause poor performance at work and school and 
diminished quality of life [3]. Suspected allergen(s) avoidance is the first-line treatment for 
these conditions. However, in many cases, exposure to a particular allergen cannot be 
completely avoided [4]. Pharmacotherapy, whether that reversing inflammation or 
controlling the effect of released mediators are not always fully effective or well tolerated 
[4]. Allergen immunotherapy is widely accepted as an efficacious treatment in allergic 
rhinitis and asthma [5-9]. Well characterized dust mite extracts have shown significant 
benefit by reducing symptoms, medication requirements and sensitivity to dust mite 
allergens [10]. Recent studies of specific immunotherapy using standardized extracts also 
showed improvement in symptoms, medication and bronchial hyperresponsiveness [10-13]. 
However, Adkinson et al [14] were unable to show any significant improvement in 
symptoms, medication use, peak flow rate, BHR or rate of asthma remission following 
multiple allergens SIT in asthmatic children. 
More recent studies in children and adults show additional positive outcomes of SIT which are 
decreased tendency for additional environmental sensitization [15], as well as a decreased 
incidence of asthma in treated allergic rhinitis patients [16]. Although the documented 
effectiveness of SIT in the treatment of allergic rhinitis and allergic asthma, the real life efficacy 
and use of this treatment option is severely limited by perceived low patient compliance [17, 
18], adverse local and systemic side effects [19, 20] and significant delay in effect after the 
initiation of therapy, all of which may lead to relatively low adherence rate [8]. 
Although there is much and convincing evidence for SIT effectiveness and efficacy from 
international studies only single study has prospectively investigated the real-life efficacy 
in Iraqi patients [21]. This prospective study of patients undergoing SIT in an office 
setting to produce practical data of efficacy of house dust mite extracts for allergic 
patients in Iraq. 
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Objectives: To  
1. Determine the therapeutic efficacy of house dust mite immunotherapy in Iraqi patients 
with allergic rhinitis and asthma. 
2. Clarify whether specific immunotherapy of therapeutic benefits in patient with asthma 
and allergic rhinitis.  
2. Patients and methods 
2.1 Patients 
From January 2000 to December 2008, we selected 822 patients with allergic rhinitis and asthma 
to receive subcutaneous specific immunotherapy according to European Academy of Allergy 
and Clinical Immunology (EAACI) guidelines [22] in a double blind placebo controlled clinical 
trial. Subjects were recruited from asthma clinic in the city of Tikrit, Iraq, only subjects who 
fulfilled the GINA guidelines for mild to moderate asthma and/or allergic rhinitis [23] and had 
positive skin prick-test to Dermatophagoides pteronyssinus and/or D. farines were included. 
Subjects excluded if their PEER of <80% of predicted value recorded on 3 occasions during the 
2 week prior to randomization, with positive SPT to animals and pets at home; asthma 
exacerbation during the last month prior to first visit, forced expiratory volume at 1 second 
(FEV1) of <60% predicted during the screening visits, had any serious chronic underlying 
illness. Patients were evaluated by medical history, clinical examination and skin prick test 
with common allergen. All data were collected prospectively, including information on 
exposure, social factors, additional diagnosis and medication usage, family history of allergic 
diseases, exposure to house pets, active or passive smoking, measures of treatment efficacy, 
and patients’ satisfaction as well as local and systemic reactions to the SIT shots. The protocol 
was approved by Tikrit University College of Medicine Ethical Committee and informed 
written consent taken from each patient. After patient selection, they were randomized to SIT 
and/or placebo and pharmacotherapy. The two groups were comparable at baseline (Table-1). 
 
Variable Immunotherapy Placebo P value 
Patients no. 411 411 NS 
Female/Male 198/213 194/217 NS 
Defaulted 73(18%) 94(23%) NS 
Patients for analysis 338(82%) 317(77%) NS 
Age range 6-65 6-65 NS 
Age mean 32±15 31±18 NS 
Clinical history 
AR 52(15%) 54(17%) NS 
Asthma 115(34%) 107(34%) NS 
AR+ Asthma 171(51%) 156(49%) NS 
Use of medication 
Antihistamine 270(80%) 269(85%) NS 
Glucocorticoids 135(39%) 127(40%) NS 
Β2-mimetics 166(49%) 149(47%) NS 
Mast cell stabilizer 101(30%) 111(35%) NS 
Table 1. Patient characteristics. 
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2.2 Asthma and allergic rhinitis diagnosis 
The diagnosis of asthma and classification was performed by specialist physicians based on 
the National Heart Blood and Lung Institute / World Health Organization (NHLBI/WHO) 
workshop on the Global Strategy for Asthma [24]. Allergic rhinitis diagnosis was performed 
according to previously reported guidelines [25].  
2.3 Lung function test 
Computerized Spirometer (Autosphiror, Discom-14, Chest Corporation, and Japan) was 
used for measurement of FEV1 predicted percent of the patients at their enrollment in the 
study and when indicated according to studies design. 
2.4 Skin prick test 
The skin prick tests were performed for all patients and control and evaluated in accordance 
with European Academy of Allergy and Clinical Immunology subcommittee on allergy 
standardization and skin tests using standards allergen panel (Stallergen, France). The panel 
for skin test include: dust mite ( Dermatophagoides farina, Dermatophagoides 
peteronyssinus), Aleternaria, Cadosprium, Penicillum mixture, Aspergillus mixture, Grasses 
mixture, Feather mixture, Dog hair, Horse hair, Cat fur, Fagacae, Oleaceae, Betulaceae, 
Plantain, Bermuda grass, Chenopodium and Mugworth. All tests were performed in the 
outpatient Asthma and Allergy Centre, Mosul by a physician using a commercial allergen 
extracts (Stallergen, France) and a lancet skin prick test device. A wheal diameter of 3 mm or 
more in excess of the negative control was considered as positive test result.  
2.5 Allergen extracts for SCIT 
Therapeutic vaccines containing allergen extracts were purchased from Stallergen, France. 
Both aqueous and glycenerated extracts were used to achieve a concentrate of 1:100 w/v of 
the mixed extract. In standardized extracts the stock formulation was prepared by tenfold 
dilution. Separate vial was used for allergen extract to reduce proteolysis degradation. All 
extracts were stored at 8 0C . Therapeutic vaccine varied with each individual patient based 
on specific allergen identified during testing. Moist patients received a variety of 
aeroallergen combination.  
2.6 SCIT protocol 
The treatment protocol is of two stage, the attack and maintenance stages. The attack treatment 
with gradual increase in dose and concentration of vaccine content were carried weekly for a 
period of 20 weeks. The vaccine is injected by deep subcutaneous route in the posterior aspect 
of upper arm. The maintenance treatment dose given in a constant dose every 15 days and 
then every 4 or 6 weeks interval. The interval between two maintenance injections must not 
exceed 6 weeks. Local reaction size was measured 20 minutes after each injection. Observed 
large local reactions (more than 20 mm wheal size) mandated a repeat of the same dose on the 
next visit, while systemic allergic reactions (skin, respiratory, cardiovascular, and / or 
gastrointestinal) required a two fold reduction in vaccine concentration. Maintenance dose 
was set in most cases at 0.5 of the stock standardized extracts. 
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2.7 Immunotherapy schedule 
Immunotherapy was given in term of conventional schedule. Conventional Immunotherapy 
build- up was typically given as injection per week until the maintenance dose was reached 
and it was given once monthly. Allergen vaccines were administered subcutaneously 
according to EAACI guidelines [26] after the patients had given their informed consent. 
3. Evaluation of treatment efficacy 
3.1 Symptom score 
A 10 cm visual analogue scales from 0=absent to 10=sever symptoms, for each symptom: 
rhinorrhoea, nasal congestion, nasal itching, ocular itching, sneezing, asthma symptoms 
(chest tightness, shortness of breath, cough) and wheezing as recommended by the ARIA 
review [27]. A change of 2 or more points on this scale is considered a clinically significant 
change with consequent significant change in the patient quality of life. 
3.2 Medication score 
Medication usage was recorded by patients on a VAS from 0=no medication to 10=repeated 
daily use of nasal corticosteroids, antihistamine oral medication, eye drops, inhaler 
corticosteroids, systemic corticosteroids, and beta agonists. 
Patients graded their symptoms retrospectively at each visit. The use of rescue medication 
was recorded on the diary card in addition to regular medications. 
3.3 Determination of serum eosinophil cationic protein 
Serum ECP was determined by ELISA kit (MBL MESCACUP ECP TEST) from Medical and 
Biological Laboratories Co. LTD, Japan. Serum ECP determined by ELISA kit (MBL 
MESCACUP ECP TEST) from Medical and Biological Laboratories Co, LTD, Japan. This 
ELISA detects s human ECP with a minimum detection limit of 0.125 ng/ml. The test 
performed according to the instruction of manufacturer. Briefly, In the wells coated with 
antihuman ECP monoclonal antibody, 100 ul of diluted serum samples ( 1:5 sample 
diluents) or standards were added and incubated for 60 minutes at room temperature (20 - 
25 0C ). After washing for 4 times, a 100ul of peroxidase conjugated antihuman ECP 
polyclonal antibody is added into the wells and incubated for 60 minutes at room 
temperature. After another 4 times washing, a 100 ul of peroxidase substrate reagent is 
added to each well and the plate incubated for 10 minutes at room temperature. The add 100 
ul of stop solution (0.5 mol/l H2SO4) and read the absorbance at 450 nm using a microplate 
reader. The concentration of ECP is calibrated from a standard curve based on reference 
standards. 
3.4 Statistical analysis and data collection 
The results of the study are reported as ratios and/or percentage of the entire cohort. Paired 
sample t-test was used for the comparison of symptoms and medication scores. Chi square 
test was used for comparison of the SPF and pulmonary function test in both groups, using 
SPSS computer package. P values of < 0.05 were considered significant.  
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4. Results 
A total of 822 patients were randomized into two treatment groups (411 for each). Of them 
167 subject defaulted during the trial (73 subjects, 18% in the SIT group; 94 subjects, 23% in 
placebo group). In most cases this was due to logistical barriers, work schedule, travel 
distance to the clinic and patients and some doctors wrong opinion regarding SIT. Thus 655 
subjects were eligible for analysis (338 subjects, 82% in the SIT group; 317 subjects, 77% in 
the placebo group), with age range of 6-65 years (Mean 32±15 for SIT group and 31±18 for 
the placebo group), completed at least 3 years of treatment. There was no significant 
difference in the frequency of AR, Asthma and AR with asthma between immunotherapy 
and placebo groups. 
4.1 Asthma group 
A negative PFT was demonstrated in 87% of asthmatic patients receiving SIT and in 91% of 
patients in placebo group (P=0.0001). In addition PFT improvement was demonstrated in 
67% in SIT group and in 19% of placebo group (P=0.0001). Symptom score reduced from 
7.56±1.84 to 3.30±1.74 in SIT group (P=0.0001), while it was reduced from 7.63±1.66 to 
7.11±2.65 in placebo group (P=0.08). Medication score significantly declined from 5.38±1.12 
to 2.20±0.90 in SIT group. While in placebo it was reduced from 5.30±1.41 to 4.94±1.31 in the 
placebo group (P=0.05). Combined symptom and medication score significantly (P=0.0000) 
declined from 6.64±1.48 to 2.73±0.97 in SIT group. In placebo group the reduction was not 
significant (P=0.99). Serum ECP reduced significantly (P=0.000) in both SIT (29.3±7.21 to 
15.3±4.11) and placebo (27.1±6.14 to 17.2±3.27). Table -2. 
Variables Immunotherapy Placebo P value 
No of patients 115 107  
SPT negative 87% 9.1% 0.0001 
PFT improvement  67% 19% 0.0001 
Symptom score 
Pre- treatment  7.56(0.84) 7.63(0.66) 0.49 
Post-treatment  3.30(0.74) 5.56(0.65) 0.0001 
P value 0.0001 0.0004  
Medication score 
Pre-treatment  5.38(1.12) 5.30(1.01) 0.94 
Post-treatment  2.20(0.90) 3.84(1.11) 0.001 
P value 0.0003 0.002  
Combined symptom and medication score 
Pre-treatment  6.64(1.48) 6.47(1.47) 0.39 
Post –treatment 2.73(0.97) 4.70(1.25) 0.0001 
P value 0.0001 0.0001  
ECP 
Pre –treatment 29.3(7.21) 27.1(6.14) 0.01 
Post –treatment 15.3(4.11) 17.2(3.27) 0.0002 
P value 0.0001 0.0001  
Table 2. Response to SCIT in patients with asthma. 
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4.2 Allergic rhinitis group 
After 3 years of intervention, negative SPT demonstrated in 81% of patients receiving SIT 
and in 19% of placebo group (P=0.000). Symptom score reduced significantly (P=0.0001) 
from 6.61±1.62 to 2.71±0.74 in SIT group. The reduction of symptom score in placebo group 
was not significant (6.67±1.37 to 6.00±1.16, P=0.99). Furthermore, medication score declined 
significantly (P=0.0001) from 5.35±1.85 to 2.21±1.87 in SIT group, while the reduction was 
not significant (P=0.98) in placebo group. 
In addition, combined medication and symptom score was significantly reduced (P=0.0001) 
from 6.12±1.7 to 2.52±1.78 in SIT group, while the reduction in placebo group was not 
significant. Serum ECP reduced significantly in both SIT (19.3±7.01 to 14.2±5.10, P=0.0001) 
and placebo group (20.1±5.30 to 17.3±6.31, P=0.014) Table -3. 
Variables Immunotherapy Placebo P value 
No of patients 52 54  
SPT negative 81% 19% 0.0001 
Symptom score 
Pre-treatment  6.61(1.62) 6.67(1.37) 0.76 
Post -treatment 2.71(0.74) 5.64(1.16) 0.0001 
P value 0.0001 0.0001  
Medication score 
Pre –treatment 5.35(1.85) 5.3(2.27) 0.85 
Post –treatment 2.21(0.87) 4.10(2.44) 0.0001 
P value 0.0001 0.009  
Combined symptom and medication score 
Pre-treatment  6.12(1.7) 6.16(1.75) 0.86 
Post -treatment 2.52(0.78) 5.10(1.80) 0.0001 
P value 0.0001 0.002  
ECP 
Pre-treatment 19.3(7.01) 20.1(5.30) 0.37 
Post -treatment 14.2(5.10) 17.3(6.31) 0.0001 
P value 0.0001 0.014  
Table 3. Response to SCIT in patients with allergic rhinitis. 
4.3 Patients with both allergic rhinitis and asthma 
PFT improvement was demonstrated in 65% of SIT group while it was 25% in placebo group 
(P=0.0001). In addition, negative SPT was demonstrated in 78% of patients receiving SIT, 
while the corresponding value was 23% in placebo group (P=0.0001). 
Symptom score declined significantly (P=0.0001) from 7.56±1.87 to 3.42±1.55 in SIT group, 
while the reduction in placebo group was not significant (P=0.052). 
Medication score reduced significantly (P=0.0001) from 5.22±2.72 to 2.72±1.53 in SIT, but the 
reduction in placebo group was not significant (5.30±1.99 to 4.99±1.86, P=0.10). 
Combined symptom and medication score reduced significantly (P=0.0001) from 6.72±1.51 
to 3.18±1.63 in SIT, while the reduction in placebo group was not significant (6.32±2.72 to 
6.32±1.99, P=0.31). 
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Serum ECP reduced significantly (P=0.0001) in both SIT (34.2±13.2 to 16.3±6.72) and placebo 
group (31.1±11.7 to 19.2±5.4) Table -4. 
Variables Immunotherapy Placebo P value 
No of patients 171 156  
SPT negative 78% 23% 0.0001 
PFT improvement  65% 25% 0.0001 
Symptom score 
Pre –treatment 7.56(0.87) 7.35(0.84) 0.06 
Post – treatment 3.43(0.55) 5.69(0.87) 0.0001 
P value 0.0001 0.0001  
Medication score 
Pre –treatment 5.22(0.89) 5.30(0.79) 0.48 
Post –treatment 2.72(0.53) 4.26(0.86) 0.0001 
P value 0.0001 0.0001  
Combined symptom and medication score 
Pre-treatment  6.72(1.51) 6.62(1.29) 0.59 
Post -treatment 3.18(0.63) 5.19(1.10) 0.0001 
P value 0.0001 0.0001  
ECP 
Pre –treatment 34.2(13.20) 31.1(11.7) 0.34 
Post -treatment 16.3(6.72) 19.2(5.4) 0.0005 
P value 0.0001 0.0001  
Table 4. Response to SCIT in patients with asthma and allergic rhinitis. 
4.4 All patients 
We combined the data of the three groups together. There was a significant decline 
(P<0.0001) in symptom score from baseline value to that of after 3 years intervention in the 
SIT (P=0.0001, 7.29±1.2 to 3.18±1.54), but not in the placebo treated subjects (7.23±2.89 to 
6.93±1.85, P=0.12). Medication score significantly (P=0.0001) declined in SIT (5.38±1.05 to 
2.42±1.66), and placebo (5.31±2.38 to 4.82±2.14, P=0.03). 
The SIT resulted in significant (P=0.0001) decline in combined symptom and medication 
score (6.61±1.46 to 2.91±1.68). In addition, placebo group demonstrated a significant 
reduction (P=0.03) in combined medication and symptom score (6.27±2.37 to 
5.88±2.2).Serum ECP reduced significantly (P=0.0001) in both SIT (30.2±7.9 to 15.6±2.32) and 
placebo (27.9±6.37 to 18.2±5.8) groups. Table -5. 
Variables Immunotherapy Placebo P value 
No of patients 338 317  
SPT negative 82%(5) 17%(7) 0.0001 
PFT improvement  66(2) 22(4) 0.0001 
Symptom score 
Pre –treatment 7.29(1.20) 7.23(0.99) 0.48 
Post –treatment 3.18(0.54) 5.63(0.85) 0.0001 
P value 0.0001 0.0001  
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Variables Immunotherapy Placebo P value 
Medication score 
Pre –treatment 5.38(1.05) 5.31(1.08) 0.62 
Post treatment 2.42(0.66) 4.10(1.15) 0.0001 
P value 0.0001 0.0001  
Combined symptom and medication score 
Pre –treatment 6.61(1.46) 6.54(1.37) 0.71 
Post –treatment 2.91(0.68) 5.10(1.20) 0.0001 
P value 0.0001 0.0001  
ECP 
Pre –treatment 30.2(7.9) 27.9(6.37) 0.01 
Post -treatment 15.6(2.32) 18.2(5.8) 0.0001 
P value 0.0001 0.0001  
Table 5. Response to SCIT in all patients. 
4.5 Percentage and amount of score changes  
The SIT resulted in significantly (P=0.0001) greater subjective rating of improvement than 
placebo treatment in all four parameters (symptom score, medication score, combined 
symptom and medication score, and serum ECP). Whether the analysis performed for each 
disease condition alone (allergic rhinitis, asthma, both allergic rhinitis and asthma) or 
combined in one group (all patients). 
The results are summarized in Table -6. 
Variables Immunotherapy Placebo P value 
No of patients 338 317  
SPT negative 277 54 0.0001 
PFT improvement 223 70 0.0001 
Asthma group 
Symptom score 4.17(55.2%) 2.07(27%) 0.0001 
Medication score 3.18(59.1%) 1.46(27.5%) 0.0001 
Both scores 3.73(56.2%) 1.77(27.4%) 0.0001 
ECP 15.3(52.2%) 9.9(36.5%) 0.0001 
Allergic rhinitis group 
Symptom score 3.91(59.2%) 1.03(15.4%) 0.0001 
Medication score 3.14(59%) 1.20(22.6%) 0.0001 
Both scores 3.60(59%) 1.06(17.2%) 0.0001 
ECP 5.10(26.4%) 2.80(14%) 0.0001 
Allergic rhinitis and Asthma group 
Symptom score 4.13(55%) 1.66(22.5%) 0.0001 
Medication score 2.50(48%) 1.04(20%) 0.0001 
Both scores 3.54(53%) 1.43(22%) 0.0001 
ECP 17.90(52.3%) 11.90(38.3%) 0.0001 
All patients 
Symptom score 4.11(56.4%) 1.60(22.1%) 0.0001 
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Variables Immunotherapy Placebo P value 
Medication score 2.96(55%) 1.21(23%) 0.0001 
Both scores 3.7(56%) 1.44(22%) 0.0001 
ECP 14.60(48.3%) 9.70(35%) 0.0001 
Table 6. Reduction in clinical scores following SIT in patients with asthma and allergic 
rhinitis. 
5. Discussion 
Despite numerous studies, the role of IT in the management of asthma remains controversial 
[28, 29], and interpretation of published reports varies considerably, presumably because of 
personal bias [30]. The variability in response to SIT in allergic diseases as reported in the 
literature may be due to uncontrolled factors that differ for people receiving the same 
therapy [30]. These factors are environmental control measures, degree of allergen exposure, 
type of allergen exposure, presence of allergenic sensitivities not incorporated into the 
treatment; non-allergenic triggers of asthma such as infection or exposure chemical 
sensitizer, genetic influence and source of vaccine used in IT. Furthermore, the outcome of 
the treatment trial influenced by allergen specificity used in the treatment as well as the 
dose and treatment schedule employed in the course. 
This is the first clinical trial that evaluated the effectiveness of SIT in Iraq, and includes a 
large treatment group, in which the outcome measured using objective criteria. 
The current study shows conclusively that house dust mite SIT results in significant 
improvement in allergic rhinitis and asthma, symptoms and reduction in rescue medication 
requirement. The results of this study differ from that of less successful studies [14, 31] with 
a population more heterogeneous in their allergen sensitivities. In our study we used a 
single allergen for treatment, as the house dust mite, Dermatophagoides, was by far the 
most important allergen in our study population. However, this study finding was in 
agreement to that reported by others [10, 32-36]. 
Immunotherapy has been established as efficacious treatment for allergic rhinitis by 
seasonal pollens, dust mite, and animal allergens, some studies show controversial findings 
[30]. A recent review [37] concluded that immunotherapy is highly effective in the treatment 
of allergic rhinitis. Several reported studies have shown that immunotherapy is effective for 
the treatment of AR, both in adults and children [14, 38, 39]. 
This study indicated that HDM immunotherapy significantly reduced symptom score, 
medication score and serum ECP level. Furthermore, in patients with both AR and asthma, 
HDM IT significantly reduced the symptom score, medication score and serum ECP mean 
level. However, the response was superior in group of patients with AR alone as compared 
to group of patients with AR and asthma. This finding is consistent with that reported by 
others [33].  
Avoidance and medication provide suboptimal control of AR in up to 40% of some patient 
populations [40]. However, this study demonstrated that HDM IT induced a 59% reduction 
in combined symptom & medication score in patients with allergic rhinitis, while the 
corresponding value was 53% for patients group with asthma and AR. The reported studies 
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indicated efficacy of SIT in AR in adults and children [9, 41-45]. There are clinical and 
immunological evidence that supports the long term efficacy of SIT [46]. 
In our study we don’t use BHR to a direct stimulus such as methacholine or histamine since it 
has poor correlations with indices of airway inflammation such as sputum eosinophils [47-49]. 
Thus we used serum ECP because it is a better marker of airway inflammation in asthma as in 
correlates with sputum eosinophils [49] and PFT following IT and medication [50]. Serum ECP 
level decreased after 2 years of immunotherapy in perennial allergic rhinitis [51] and asthma 
[50]. However, the rise in serum ECP after allergen challenge was significantly attenuated after 
just 1 year of immunotherapy in asthmatic patients [52]. Our study indicated a significant 
decrease in serum ECP in both SIT and placebo treated subject. However, the reduction was 
significantly higher in SIT group as compared to placebo group for patients with AR, Asthma, 
and AR with Asthma and when the data of patients pooled together. In placebo treated group 
decline in serum ECP may be due to treatment with inhaled corticosteroids. 
When the data of three disease groups pooled together, the symptom score, medication 
score, combined score and serum ECP significantly reduced in SIT as compared to placebo 
treatment group. Furthermore, SPT negative results and PFT improvement were 
significantly higher in SIT compared to placebo group. 
In this study SIT induces a significant reduction in all parameters used in the study whether 
the patients were with AR, asthma or both combined together. SIT shows overall percent 
reduction of 54%, while it was 17.5% in placebo group. 
Based on the finding of this and other studies, single allergen SIT is likely to be beneficial to 
patients with AR, asthmatic and with both, sensitized to a dominant allergen. However, 
there are other drugs such as inhaled long acting B2-agonist and anileukotriens agents that 
might be better at symptom control and lung function improvement, SIT has some unique 
benefits [10]. 
Haugaard et al [53], reported that SIT reduce airway sensitivity to allergens, which may lead 
subsequently to reduction in frequency of exacerbation and severity of asthma triggered by 
allergen exposure. In addition, the effect of SIT may persist for at least 5-6 years after the 
end of treatment [53]. Furthermore, SIT reduces the conversion of AR to asthma [51] and 
prevents the development of new sensitization [44].  
Different studies show controversial outcome for SIT. Failure to respond to SIT may be due 
to: inadequate dose of allergen, missing allergens not identified during the allergy 
evaluation, inadequate environmental control, and exposure to non allergenic triggers. 
Systemic adverse reactions were developed in 62 (15.1%) individuals from the 411 subjects 
included in the study. None of the developed systemic reactions had life threatening 
reactions. House dust mite was with a predictive value for development of systemic adverse 
reactions (OR=2.3, p=0.0001) [54]. However, this study indicated that HDM specific 
immunotherapy was with good tolerance 
6. Conclusion 
HDM immunotherapy for 3 years significantly reduced symptom and medication use in AR, 
asthma and patients with both conditions, and prevent the consequent development of 
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asthma in patients with AR. This was associated with a greater subjective improvement in 
asthma control. 
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